Physician profile
David A Hess
NPI 1558340364
$12,720.25
in general payments reported to CMS, 2019-2025
55 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,561 · 2021: $1,802 · 2022: $1,623 · 2023: $1,539 · 2024: $2,312 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,771.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,269.03 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $1,129.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,096.85 | 2019-2025 | |
| Amgen INC. | $931.39 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $880.07 | 2020-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.95 | 2019-2024 | Jardiance |
| Abbott Laboratories | $689.75 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Aveir |
| Amarin Pharma, INC. | $650.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $484.48 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Edwards Lifesciences Corporation | $482.65 | 2020-2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $313.30 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $303.59 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.49 | 2019-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $255.61 | 2019-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $232.27 | 2020-2025 | Nexletol |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.